{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:11:15Z","timestamp":1788639075756,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cjca.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T16:30:55Z","timestamp":1389803455000},"page":"S47-S53","source":"Crossref","is-referenced-by-count":50,"special_numbering":"S","title":["Atenolol vs Nonatenolol \u03b2-Blockers for the Treatment of\u00a0Hypertension: A Meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Laura M.","family":"Kuyper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.01.006_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cjca.2012.04.001","article-title":"The evolving role of beta-adrenergic receptor blockers in managing hypertension","volume":"28","author":"Poirier","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.01.006_bib2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review","volume":"279","author":"Messerli","year":"1998","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cjca.2014.01.006_bib3","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2014.01.006_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/22201173.2006.10872455","article-title":"Are lipophilic beta-blockers preferable for peri-operative cardioprotection?","volume":"12","author":"Biccard","year":"2006","journal-title":"S\u00a0Afr J Anaesth Analg"},{"key":"10.1016\/j.cjca.2014.01.006_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.23.1.83","article-title":"Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension","volume":"23","author":"Schiffrin","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.01.006_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0002-8703(90)90174-V","article-title":"Antihypertensive effects of beta blockers administered once daily: 24-hour measurements","volume":"120","author":"Neutel","year":"1990","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.01.006_bib7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A\u00a0meta-analysis of 94,\u00a0492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2014.01.006_bib8","first-page":"CD002003","article-title":"Beta-blockers for hypertension","volume":"8","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2014.01.006_bib9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension)","volume":"338","author":"Dahlof","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib10","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib13","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.01.006_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. MRC Working Party","volume":"291","year":"1985","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.01.006_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party","volume":"304","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.01.006_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/01.STR.24.4.543","article-title":"Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group","volume":"24","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2014.01.006_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"Coope","year":"1986","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.01.006_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000107813","article-title":"Atenolol in secondary prevention after stroke. The TEST Study Group","volume":"5","author":"Eriksson","year":"1995","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.cjca.2014.01.006_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blockers oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). The IPPPSH Collaborative Group","volume":"3","year":"1985","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.01.006_bib20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/jama.1982.03330160052024","article-title":"Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. Results of long-term therapy","volume":"248","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.01.006_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0954-6820.1986.tb02790.x","article-title":"Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic","volume":"220","author":"Berglund","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.cjca.2014.01.006_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.01.006_bib23","doi-asserted-by":"crossref","first-page":"182S","DOI":"10.1093\/ajh\/5.6.182S","article-title":"Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial","volume":"6","author":"Yurenev","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.01.006_bib24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.01.006_bib25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib26","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.01.006_bib27","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.01.006_bib28","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A\u00a0calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.01.006_bib29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.01.006_bib31","first-page":"779","article-title":"Elderly hypertensives: how are they different?","volume":"14","author":"Franklin","year":"2012","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.cjca.2014.01.006_bib32","first-page":"711","article-title":"Dilemmas in treating hypertension in octogenerians","volume":"14","author":"Tabriziani","year":"2012","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.cjca.2014.01.006_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11906-011-0215-x","article-title":"Update on pathophysiology and treatment of hypertension in the elderly","volume":"13","author":"Cohen","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2014.01.006_bib34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMcp071137","article-title":"Isolated systolic hypertension in the elderly","volume":"357","author":"Chobanian","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.01.006_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CRD.0b013e31825d0a44","article-title":"Effects of antihypertensive drugs on arterial stiffness","volume":"20","author":"Dudenbostel","year":"2012","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cjca.2014.01.006_bib36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ajh.2008.156","article-title":"Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection","volume":"21","author":"Mahmud","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.01.006_bib37","doi-asserted-by":"crossref","unstructured":"The CAF\u00c9 Investigators; for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006;113:1213-25.","DOI":"10.1161\/CIRCULATIONAHA.105.595496"},{"key":"10.1016\/j.cjca.2014.01.006_bib38","unstructured":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National High Blood Pressure Education Program. Bethesda, MD, National Heart, Lung, and Blood Institute; 2004; Report No. 04\u20135230."},{"key":"10.1016\/j.cjca.2014.01.006_bib39","unstructured":"Hypertension: the clinical management of primary hypertension in adults. Update of Clinical Guidelines 18 and 34 [Internet]; 2011. National Clinical Guideline Centre (UK). London Royal College of Physicians (UK). National Institute for Health and Clinical Excellence."},{"key":"10.1016\/j.cjca.2014.01.006_bib40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cjca.2013.01.005","article-title":"The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"29","author":"Hackam","year":"2013","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T05:40:17Z","timestamp":1597383617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X14000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0828282X14000105"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.01.006","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}